Biotech & AI drug discoveryWIRED

New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent

A new mRNA vaccine personalized to a patient's tumor reportedly reduced the risk of melanoma recurrence by over 40 percent in a Phase 3 trial, which the outlet describes as another example of the promise of mRNA vaccines in treating cancer.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-24T11:30:00+00:00

Published here2026-10-24T16:22:06+00:00

Original source

WIRED

Media report · consult original reporting

Read the original ↗https://www.wired.com/story/new-melanoma-vaccine-reduces-risk-of-tumor-reoccurrence-by-over-40-percent/

Original headline

New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.